Loading
companiesCompany
Curium
Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.
Overview
Curium is a Paris-based private radiopharmaceutical group, one of the largest in nuclear medicine, supplying SPECT and PET isotopes and generators and developing 177Lu-PSMA-I&T as a competitor to Pluvicto in prostate cancer. Its ECLIPSE phase 3 trial of 177Lu-PSMA-I&T met its radiographic progression-free survival endpoint in taxane-naive metastatic castration-resistant prostate cancer, a Japanese registrational trial with PeptiDream and PDRadiopharma enrolled its first patient in February 2026, and the regulatory submission plan is under discussion with the FDA. OnCo links it to DOTATATE imaging agents, samarium-153 lexidronam, radionuclide generators and the therapeutic isotope supply chain. Whether a second lutetium PSMA agent can differentiate on supply and price rather than efficacy is the open question. The manufacturing cost of radioactive medicines is the bottleneck it bears on.
Headquarters
Paris, FR
Scorecard
All companies#93of 1244 companies, score 52
- approved products +18
- phase 3 +3
- targets +4
- modalities +4
- regions +3
- 24-month regulatory events +2
- registry trials +18
3 approved, 1 in phase 3, 0 earlier, 2 targets, 77 registry studies. Formula on the scorecards page.
Manufacturing
Capacity map- Curium Petten Petten, NLRadioisotope production, Radiopharmaceutical manufacturing
Website
Phase 3Radioligand therapy (beta)
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
ApprovedPET imaging agent
Piflufolastat F-18 / Pylarify TruVu · Pylarify
Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026.
ApprovedPET radiotracer (somatostatin receptor ligand)
Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
ApprovedBone-seeking therapeutic radiopharmaceutical (beta emitter)
Samarium-153 lexidronam · Quadramet
Quadramet (samarium-153 lexidronam) is a radioactive bone-seeking injection that lodges in bone metastases and irradiates them from inside, approved in 1997 to relieve pain from prostate, breast and other cancers spread to bone. Most patients get relief within one to two weeks, but marrow suppression follows at three to five weeks, and radium-223 and PSMA radioligands have largely replaced it.
Similar pages
- CompanyEckert & Ziegler
Shares Radionuclide generators and cold kits, Radiopharmacy and cyclotron networks, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- CompanyIRE (Institut national des Radioéléments)
Shares Radionuclide generators and cold kits, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- CompanyLantheus
Shares Samarium-153 lexidronam, 177Lu-PSMA-I&T, Radionuclide generators and cold kits, Piflufolastat F-18 / Pylarify TruVu.
- CompanyANSTO (Australian Nuclear Science and Technology Organisation)
Shares Radiopharmacy and cyclotron networks, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- CompanyPETNET Solutions (Siemens Healthineers)
Shares Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyCardinal Health Nuclear & Precision Health Solutions
Shares Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyITM Isotope Technologies Munich
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Radiopharmaceutical GMP and releasing a drug that decays, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Manufacturing cost and time for living and radioactive medicines.
- TechnologyActinium-225 supply: thorium stocks, accelerators and radium targets
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays, Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
cancers
fronts
technologies
Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)Radionuclide generators and cold kitsRadiopharmaceutical GMP and releasing a drug that decaysRadiopharmacy and cyclotron networksResearch reactors for medical isotopes (Mo-99, Lu-177, I-131)Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)
drugs
Phase 3Radioligand therapy (beta)
ApprovedPET radiotracer (somatostatin receptor ligand)
Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet
ApprovedPET imaging agent
Piflufolastat F-18 / Pylarify TruVu · Pylarify
ApprovedBone-seeking therapeutic radiopharmaceutical (beta emitter)
Samarium-153 lexidronam · Quadramet